AUS
NZ
UK
CA
USA
IND
Healthcare
4DMedical: Philips Deal Sparks Fresh Valuation Questions
December 08, 2025 05:40 PM AEDT| By Sam4DMedical’s expanded Philips CT:VQ distribution adds commercial visibility for North America. The next phase hinges on execution: deployment pace, workflow fit, sustained clinical usage, and disciplined scaling.
4DMedical: What the Philips Deal Signals for Valuation Debate
December 08, 2025 05:30 PM AEDT| By Sam4DMedical’s Philips-linked CT:VQ rollout strengthens commercial visibility for North America. The next phase depends on implementation pace, clinical uptake, and whether scaling costs remain aligned with real-world adoption.
Learn a Simple Way to Read (ASX:CSL) Value Inside the ASX 200
December 08, 2025 03:18 PM AEDT| By SamThis article explains CSL’s business mix and the key value signals used in market commentary, helping readers interpret durability, resilience and execution quality in a large Australian healthcare company.
Imugene Advances Azer-cel Registration with FDA Backing
December 08, 2025 12:51 PM AEDT| By SamImugene Ltd (ASX:IMU) secures FDA alignment to advance azer-cel CAR T therapy into pivotal trials for high-need lymphoma patients.
Breakthrough Antibiotic Advance Positions R327 for Wider Global Use
December 05, 2025 08:09 PM AEDT| By SamThis article explores the latest progress surrounding R three two seven, its growing patent footprint, ongoing international trials, and how these developments may shape future treatment pathways.
Azer-cel Trial Momentum Puts Imugene in the Spotlight
December 05, 2025 06:24 PM AEDT| By SamThis article explains the latest clinical progress from Imugene’s azer-cel study, the response trends observed across two patient groups, and how the development fits into broader biotechnology activity on the ASX stock market.
CSL (ASX:CSL): Reset, Buyback Focus And What To Watch Next
December 05, 2025 12:53 PM AEDT| By SamCSL is navigating a reset phase while progressing capital management and expanding manufacturing capability. Investors are watching execution signals, facility milestones and communication clarity as the healthcare heavyweight works to rebuild moment...
Entropy Doses First Patient in IV Psilocin BED Trial
December 05, 2025 11:41 AM AEDT| By SamEntropy has dosed the first patient in its TRP-8803 trial for binge eating disorder, using IV psilocin with supportive therapy. The next focus is enrolment progress and the first cohort readout.
A Expanded Imaging Alliance Positions 4DMedical for Wider Clinical Reach
December 04, 2025 04:56 PM AEDT| By SamThis article explores 4DMedical’s expanded CT:VQ distribution agreement, analysing its industry impact, commercial strategy, and broader relevance across imaging innovation within the evolving landscape of global medical technology.
Value Check on Ansell Limited: Is the Market Missing the Bigger Picture?
December 04, 2025 03:14 PM AEDT| By SamA deep dive into the valuation outlook for Ansell (ASX:ANN), exploring how its projected cash flows shape market views, why its present pricing raises questions, and how investors analyse long-term fair value within the wider landscape of the ASX sto...
Is (ASX:ANN) Misread by Markets in the ASX 200 Value Debate?
December 04, 2025 02:47 PM AEDT| By SamAnsell’s valuation debate shows how markets weigh risk against cash-flow durability. The most important drivers are discount rate assumptions, long-run growth views, and confidence in steady cash conversion.
Pro Medicus (ASX:PME) Faces Data Breach: What Investors Should Know
December 04, 2025 12:36 PM AEDT| By SamPro Medicus (ASX:PME) confirmed an isolated data breach affecting a single email inbox at its subsidiary Visage Imaging. No client systems, patient data, or financial operations were impacted.
ECS Botanics Sets Stage for AVANI AVA Women’s-Health Cannabis Launch in 2026
December 04, 2025 12:16 PM AEDT| By SamECS Botanics (ASX:ECS) is preparing to introduce AVANI AVA, a women-centered medicinal cannabis range arriving in early twenty-six. This detailed article explores the strategic expansion, product design, industry relevance
ASX 300 Sees Quiet Aged-Care Move Drawing New Interest
December 04, 2025 11:05 AM AEDT| By SamA deep dive into the latest aged-care portfolio shift involving Regis Healthcare (ASX:REG), exploring how a major divestment aligns with sector trends across the broader ASX stock market and the evolving landscape of Australian healthcare services.
Philips Partnership Boosts 4DMedical’s Global Expansion
December 03, 2025 03:02 PM AEDT| By Team Kalkine MediaThis article explores how 4DMedical (ASX:4DX) has broadened its agreement with global technology group Philips to distribute its CT-based lung-imaging platform across North America.
Insider Moves and Market Shifts at Paragon Care (ASX:PGC)
December 03, 2025 10:52 AM AEDT| By Team Kalkine MediaThis article explores the shifting dynamics at Paragon Care (ASX:PGC), focusing on insider activity, market response, and shareholder structure. It breaks down how different ownership groups influence decision-making and how the broader ASX stock mar...
Imugene (ASX:IMU) Advances CAR-T Therapy with 82% Response Rate
December 02, 2025 05:46 PM AEDT| By Team Kalkine MediaImugene Ltd (ASX:IMU) continues to demonstrate progress in immuno-oncology with azer-cel, presenting meaningful developments in lymphoma treatment and expanding its footprint in the ASX stock market.
Unlocking PME Shares: Key Insights into Pro Medicus (ASX:PME)
December 02, 2025 05:37 PM AEDT| By Team Kalkine MediaExplore the essential insights into Pro Medicus Ltd (ASX:PME) shares, highlighting financial health, software innovations, and key metrics that shape performance in the ASX stock market. Learn what makes PME a notable presence in healthcare technolog...
Imugene Advances Azer-cel as Clinical Progress Gain Momentum
December 01, 2025 08:11 PM AEDT| By Team Kalkine MediaImugene Ltd (ASX:IMU) continues to advance its immuno-oncology pipeline as its off-the-shelf CAR-T program azer-cel delivers encouraging results in people with varied forms of blood cancer. This update explores response outcomes, clinical expansion
CSL Ltd Continues to Lead Australia’s Healthcare Innovation
November 28, 2025 03:10 PM AEDT| By Team Kalkine MediaThis article explores CSL Ltd (ASX:CSL), a major name in the global biotechnology landscape, focusing on its growth drivers, business structure, and position within the ASX stock market while avoiding any investment guidance terminology.
Advertise your brand on Kalkine Media